<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:npr="https://www.npr.org/rss/" xmlns:nprml="https://api.npr.org/nprml" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
  <channel>
    <title>NPR: paxlovid</title>
    <link>https://www.npr.org/templates/story/story.php?storyId=1066866646</link>
    <description>paxlovid</description>
    <language>en</language>
    <copyright>Copyright 2024 NPR - For Personal Use Only</copyright>
    <generator>Story API Shim 1.2.24</generator>
    <lastBuildDate>Wed, 07 May 2025 00:10:30 -0400</lastBuildDate>
    <image>
      <url>https://media.npr.org/images/podcasts/primary/npr_generic_image_300.jpg?s=200</url>
      <title>NPR: paxlovid</title>
      <link>https://www.npr.org/tags/1066866646/paxlovid</link>
    </image>
    <item>
      <title>In a pandemic milestone, the NIH ends guidance on COVID treatment</title>
      <description>The National Institutes of Health is sunsetting its influential COVID-19 treatment guidelines, used by millions of doctors to guide care during the pandemic.</description>
      <pubDate>Tue, 19 Mar 2024 09:01:05 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2024/03/19/1239276507/nih-covid-treatment-guidelines</link>
      <guid>https://www.npr.org/sections/health-shots/2024/03/19/1239276507/nih-covid-treatment-guidelines</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2024/03/18/gettyimages-1407371820-d49c4ec781ded93e833d8cbc78cb4c5c4bae5a7b.jpg' alt='Pfizer's Paxlovid combines two antiviral drugs to fight the virus that causes COVID-19.'/><p>The National Institutes of Health is sunsetting its influential COVID-19 treatment guidelines, used by millions of doctors to guide care during the pandemic.</p><p>(Image credit: Joe Raedle)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1239276507' />]]></content:encoded>
      <dc:creator>Pien Huang</dc:creator>
    </item>
    <item>
      <title>Top COVID FAQs of 2023: Staying safe at home, flying tips, shot combos, new variant</title>
      <description>How do I stay safe now that the public health emergency is over? We answer questions on boosters, risks when flying — and the new JN.1 variant.</description>
      <pubDate>Thu, 21 Dec 2023 14:19:16 -0500</pubDate>
      <link>https://www.npr.org/sections/goatsandsoda/2023/12/21/1219990346/top-covid-faqs-of-2023-staying-safe-at-home-flying-tips-shot-combos-new-variant</link>
      <guid>https://www.npr.org/sections/goatsandsoda/2023/12/21/1219990346/top-covid-faqs-of-2023-staying-safe-at-home-flying-tips-shot-combos-new-variant</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2023/12/21/nervousgettingout-there_3_custom-f3396345ed3844bb01b58254adcdfe9ddc51c169.jpg' alt='undefined'/><p>How do I stay safe now that the public health emergency is over? We answer questions on boosters, risks when flying — and the new JN.1 variant.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1219990346' />]]></content:encoded>
      <dc:creator>Marc Silver</dc:creator>
    </item>
    <item>
      <title>Coronavirus FAQ: &apos;Emergency&apos; over! Do we unmask and grin? Or adjust our worries?</title>
      <description>Now that official COVID emergency declarations have ended, how should people evaluate their risk of SARS-CoV-2? That&apos;s the subject of our frequently asked questions offering.</description>
      <pubDate>Fri, 12 May 2023 13:15:27 -0400</pubDate>
      <link>https://www.npr.org/sections/goatsandsoda/2023/05/12/1173993754/coronavirus-faq-emergency-over-do-we-unmask-and-grin-or-adjust-our-worries</link>
      <guid>https://www.npr.org/sections/goatsandsoda/2023/05/12/1173993754/coronavirus-faq-emergency-over-do-we-unmask-and-grin-or-adjust-our-worries</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2023/05/11/gettyimages-1250512939-54afa7d9267b218ded2f777784aca17f372e6958.jpg' alt='A poster in Kolkata, India, from peak pandemic days sends a message to mask up. Now that the official COVID-19 global emergency is no longer in effect, some folks are thrilled to stop masking — but others wonder if it's a good idea to keep up certain precautions.'/><p>Now that official COVID emergency declarations have ended, how should people evaluate their risk of SARS-CoV-2? That's the subject of our frequently asked questions offering.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1173993754' />]]></content:encoded>
      <dc:creator>Fran Kritz</dc:creator>
    </item>
    <item>
      <title>Coronavirus FAQ: Is Paxlovid the best treatment? Is it underused in the U.S.?</title>
      <description>The drug is the most effective way to cut the risk of severe disease. It&apos;s heading to China now. Yet the drug is underused in some places. Why? And are there options if you&apos;re not a good candidate?</description>
      <pubDate>Fri, 16 Dec 2022 08:56:21 -0500</pubDate>
      <link>https://www.npr.org/sections/goatsandsoda/2022/12/16/1142586058/coronavirus-faq-is-paxlovid-the-best-treatment-is-it-underused-in-the-u-s</link>
      <guid>https://www.npr.org/sections/goatsandsoda/2022/12/16/1142586058/coronavirus-faq-is-paxlovid-the-best-treatment-is-it-underused-in-the-u-s</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2022/12/13/gettyimages-1407371881_custom-f9332bfcebac0bf808e2dba2d6219e0182f569af.jpg' alt='Pfizer's Paxlovid pills are considered the most effective treatment to prevent severe COVID. They're about to be sold in China. But they are reportedly underused in the U.S.'/><p>The drug is the most effective way to cut the risk of severe disease. It's heading to China now. Yet the drug is underused in some places. Why? And are there options if you're not a good candidate?</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1142586058' />]]></content:encoded>
      <dc:creator>Fran Kritz</dc:creator>
    </item>
    <item>
      <title>President Biden&apos;s COVID symptoms are improving, his doctor says</title>
      <description>Biden&apos;s physician says the president&apos;s symptoms &quot;continue to improve significantly&quot; and that he is now mainly dealing with a sore throat.</description>
      <pubDate>Sun, 24 Jul 2022 12:13:31 -0400</pubDate>
      <link>https://www.npr.org/2022/07/24/1113263372/biden-coronavirus-symptoms-update</link>
      <guid>https://www.npr.org/2022/07/24/1113263372/biden-coronavirus-symptoms-update</guid>
      <content:encoded><![CDATA[<p>Biden's physician says the president's symptoms "continue to improve significantly" and that he is now mainly dealing with a sore throat.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1113263372' />]]></content:encoded>
      <dc:creator>Shauneen Miranda</dc:creator>
    </item>
    <item>
      <title>Biden tested positive for COVID again after taking Paxlovid. That was a known risk</title>
      <description>Paxlovid has been highly effective at reducing the risks of hospitalization and death, but some patients report a &quot;Paxlovid rebound,&quot; in which the disease returns.</description>
      <pubDate>Thu, 21 Jul 2022 15:02:18 -0400</pubDate>
      <link>https://www.npr.org/2022/07/21/1112740916/paxlovid-president-biden-covid-antiviral-treatment</link>
      <guid>https://www.npr.org/2022/07/21/1112740916/paxlovid-president-biden-covid-antiviral-treatment</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2022/07/21/gettyimages-1407371881_custom-a31b445180e005cac615fee50f62f28c6b1e8148.jpg' alt='Pfizer's Paxlovid pills are seen on display. The medicine received an emergency use authorization for COVID-19 last December.'/><p>Paxlovid has been highly effective at reducing the risks of hospitalization and death, but some patients report a "Paxlovid rebound," in which the disease returns.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1112740916' />]]></content:encoded>
      <dc:creator>Bill Chappell</dc:creator>
    </item>
    <item>
      <title>3 ways to get COVID pills, if you&apos;ve just tested positive</title>
      <description>Some people have had trouble getting Paxlovid pills quickly, despite the administration&apos;s effort to ease access after a COVID test confirms infection.</description>
      <pubDate>Wed, 11 May 2022 11:53:46 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2022/05/11/1097698090/3-ways-to-get-covid-pills-if-youve-just-tested-positive</link>
      <guid>https://www.npr.org/sections/health-shots/2022/05/11/1097698090/3-ways-to-get-covid-pills-if-youve-just-tested-positive</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2022/05/09/pfizer-pr-2-36f3acd2224d210fb72fb959defbf21196bab120.jpg' alt='TK'/><p>Some people have had trouble getting Paxlovid pills quickly, despite the administration's effort to ease access after a COVID test confirms infection.</p><p>(Image credit: thomas hansmann.fotograf)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1097698090' />]]></content:encoded>
      <dc:creator>Pien Huang</dc:creator>
    </item>
    <item>
      <title>Biden will make Paxlovid, a highly effective COVID drug, available to more pharmacies</title>
      <description>The antiviral pill is available to patients older than 12 who have tested positive for COVID and are at risk for developing a severe case of the disease.</description>
      <pubDate>Tue, 26 Apr 2022 05:01:15 -0400</pubDate>
      <link>https://www.npr.org/2022/04/26/1094735822/biden-will-make-paxlovid-a-highly-effective-covid-drug-available-to-more-pharmac</link>
      <guid>https://www.npr.org/2022/04/26/1094735822/biden-will-make-paxlovid-a-highly-effective-covid-drug-available-to-more-pharmac</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2022/04/25/gettyimages-1388626466-78c8cce995db46988c2553342254829e491da4ad.jpg' alt='President Biden is seen delivering remarks on COVID-19 on March 30. On Tuesday, the White House will announce a new push to get more doses of the COVID antiviral medication Paxlovid to more Americans.'/><p>The antiviral pill is available to patients older than 12 who have tested positive for COVID and are at risk for developing a severe case of the disease.</p><p>(Image credit: Anna Moneymaker)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1094735822' />]]></content:encoded>
      <dc:creator>Tamara Keith</dc:creator>
    </item>
    <item>
      <title>Lifesaving COVID drugs are sitting unused on pharmacy shelves, HHS data shows</title>
      <description>States and health providers report they&apos;ve dispensed less than half their supply from the government, raising fears that the drugs may go to waste while people who could benefit get sicker.</description>
      <pubDate>Fri, 18 Mar 2022 05:00:26 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2022/03/18/1087380770/lifesaving-covid-drugs-are-sitting-unused-on-pharmacy-shelves-hhs-data-shows</link>
      <guid>https://www.npr.org/sections/health-shots/2022/03/18/1087380770/lifesaving-covid-drugs-are-sitting-unused-on-pharmacy-shelves-hhs-data-shows</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2022/03/17/gettyimages-1237399517_custom-59e632d75d3dd3fd05309db878fc2740fa6f87c1.jpg' alt='Treatments like monoclonal antibody infusions and antiviral pills can prevent a case of COVID-19 from becoming life-threatening. But many of the available drugs are not being used.'/><p>States and health providers report they've dispensed less than half their supply from the government, raising fears that the drugs may go to waste while people who could benefit get sicker.</p><p>(Image credit: Emily Elconin)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1087380770' />]]></content:encoded>
      <dc:creator>Pien Huang</dc:creator>
    </item>
    <item>
      <title>&apos;Test to Treat&apos; gets COVID pills to at-risk patients fast but its reach is limited</title>
      <description>The Biden administration&apos;s new program enables high-risk patients who test positive to get antiviral pills on the spot in some pharmacies. But many pharmacies won&apos;t be able to participate.</description>
      <pubDate>Tue, 08 Mar 2022 13:03:57 -0500</pubDate>
      <link>https://www.npr.org/sections/health-shots/2022/03/08/1085078893/test-to-treat-gets-covid-pills-to-at-risk-patients-fast-but-its-reach-is-limited</link>
      <guid>https://www.npr.org/sections/health-shots/2022/03/08/1085078893/test-to-treat-gets-covid-pills-to-at-risk-patients-fast-but-its-reach-is-limited</guid>
      <content:encoded><![CDATA[<p>The Biden administration's new program enables high-risk patients who test positive to get antiviral pills on the spot in some pharmacies. But many pharmacies won't be able to participate.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1085078893' />]]></content:encoded>
      <dc:creator>Pien Huang</dc:creator>
    </item>
  </channel>
</rss>